心肾代谢疾病非抗心律失常药物治疗与新发房颤:一项试验荟萃分析
在安慰剂对照试验中,射血分数降低心衰使用ACEI/ARB、MRA、SGLT2抑制剂,慢性肾病使用SGLT2抑制剂,肥胖使用GLP-1受体激动剂均与新发房颤风险降低相关,但各试验房颤事件数少且无足够把握度。
要点
- HFrEF使用ACEI/ARB、MRA或SGLT2抑制剂与新发房颤风险降低相关
- CKD使用SGLT2抑制剂、肥胖使用GLP-1受体激动剂亦见新发房颤风险降低
- 各试验房颤事件数少,均无足够把握度,结论需前瞻性预设房颤结局的RCT验证
核心结论
- 心肾代谢疾病部分非抗心律失常药物与新发房颤风险降低相关,但现有试验均无足够把握度,需前瞻性预设房颤结局的RCT验证。
研究设计与样本
- 采用Mantel-Haenszel法的随机效应荟萃分析,研究间方差用DerSimonian-Laird法估计,合并风险比(RR)及95%CI。
主要发现
- 安慰剂对照试验中,HFrEF使用ACEI/ARB者新发房颤RR 0.69(95%CI 0.60-0.80)。
- HFrEF使用MRA者新发房颤RR 0.62(95%CI 0.43-0.90),使用SGLT2抑制剂者RR 0.62(95%CI 0.44-0.87)。
- CKD使用SGLT2抑制剂者新发房颤RR 0.53(95%CI 0.33-0.85)。
- 肥胖使用GLP-1受体激动剂者新发房颤RR 0.79(95%CI 0.63-0.99)。
- 各试验房颤事件数少,且无一试验对新发房颤有足够把握度。
临床怎么用
- 对HFrEF、CKD和肥胖患者选择上述药物时,可将新发房颤风险降低作为附带获益信息参考。
- 不应仅以预防新发房颤为目的处方这些药物,现有证据把握度不足。
局限性
- 多数试验通过不良事件报告识别房颤,仅15项以房颤为预设终点,存在漏诊与报告偏倚可能。
- 各试验房颤事件数少,均无足够把握度评估新发房颤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Atrial fibrillation (AF) disease burden is increasing. Pharmacotherapy of cardio-renal-metabolic diseases may prevent incident AF. This meta-analysis estimates the effect of different pharmacotherapies on risk of incident AF across cardio-renal-metabolic diseases. METHODS: The Medline, Embase, and Cochrane Central databases were searched to 7 October 2025 for randomized clinical trials (RCTs) comparing the effect of a non-antiarrhythmic cardio-renal-metabolic medication with control or another agent for incident AF. Random-effects meta-analysis using the Mantel-Haenszel method, with between-study variance estimated using the DerSimonian-Laird method, was performed to synthesize risk ratios (RR) with 95% confidence intervals (CI). RESULTS: Two hundred and forty-nine RCTs involving 745 041 patients were included, of which 207 identified AF through adverse event reports, 161 were placebo-controlled, and 15 had AF as a pre-specified endpoint. In placebo-controlled trials, significant differences in incident AF were observed with treatment of heart failure with reduced ejection fraction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (RR 0.69, 95% CI 0.60-0.80), mineralocorticoid receptor antagonists (RR 0.62, 95% CI 0.43-0.90), and sodium-glucose co-transporter 2 (SGLT2) inhibitors (RR 0.62, 95% CI 0.44-0.87); treatment of chronic kidney disease with SGLT2 inhibitors (RR 0.53, 95% CI 0.33-0.85); and treatment of obesity with glucagon-like peptide-1 receptor agonists (RR 0.79, 95% CI 0.63-0.99). However, the number of AF events per trial was low and none were adequately powered for incident AF. CONCLUSIONS: Prospective RCTs with AF as a pre-specified outcome should be integrated into the design of future trials of cardio-renal-metabolic medications to determine whether they reduce incident AF.
引用
- Raveendra K, Nadarajah R, Larvin H, et al. Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis. Eur Heart J. 2026. PMID: 41603358. doi:10.1093/eurheartj/ehag021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。